GlassScriptPhysician profile
Mark C Cascione
NPI 1447249115
$1,213,056.43
in general payments reported to CMS, 2019-2025
91 companies · $116K in 2025
The $116K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $343K · 2020: $86K · 2021: $144K · 2022: $221K · 2023: $171K · 2024: $133K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $303K · Consulting Fee: $51K · Travel and Lodging: $35K · Food and Beverage: $31K · Education: $76.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $302,512.28 |
| Consulting Fee | $50,617.36 |
| Travel and Lodging | $34,687.60 |
| Food and Beverage | $31,483.92 |
| Education | $76.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $265,117.89 | 2019-2025 | |
| Genentech USA, INC. | $189,146.43 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biogen, INC. | $177,601.40 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| E.R. Squibb & Sons, L.L.C. | $166,030.37 | 2020-2025 | Zeposia |
| Tg Therapeutics, INC. | $99,791.83 | 2021-2025 | Briumvi |
| Emd Serono, INC. | $62,043.71 | 2019-2025 | Mavenclad |
| Celgene Corporation | $49,314.76 | 2019-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $41,533.66 | 2019-2025 | Ultomiris, Soliris |
| Vanda Pharmaceuticals INC. | $41,036.32 | 2020-2025 | Ponvory |
| Novartis Pharmaceuticals Corporation | $36,967.79 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $31,776.94 | 2020-2024 | Ponvory, Spravato |
| Sanofi-Aventis U.S. LLC | $26,999.90 | 2019-2021 | |
| Abbvie INC. | $3,578.49 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $1,505.45 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $1,459.19 | 2019-2025 | Vyepti, Rexulti |
Show all 88 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,384.68 | 2019-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $1,313.73 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $1,249.22 | 2019-2022 | |
| Pfizer INC. | $1,095.39 | 2023-2025 | |
| Lilly USA, LLC | $987.47 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Genentech, INC. | $912.90 | 2019-2025 | Ocrevus |
| Octapharma USA, INC. | $833.79 | 2022-2025 | Panzyga, Cutaquig |
| Neurocrine Biosciences, INC. | $723.32 | 2020-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $710.16 | 2021-2025 | Hyqvia, Gammagard |
| Argenx US, INC. | $659.50 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Adamas Pharmaceuticals, INC. | $578.15 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $573.02 | 2023-2024 | Nuedexta, Rexulti |
| Biohaven Pharmaceuticals, INC. | $524.33 | 2020-2021 | |
| Acorda Therapeutics, INC | $509.13 | 2019-2024 | Inbrija, Ampyra |
| Horizon Therapeutics Plc | $486.74 | 2021-2023 | Uplizna |
| Csl Behring | $439.30 | 2020-2025 | Hizentra |
| Sunovion Pharmaceuticals INC. | $399.92 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $395.42 | 2019-2025 | Nuplazid |
| Eisai INC. | $380.30 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $373.82 | 2019-2023 | |
| Amneal Pharmaceuticals LLC | $350.31 | 2020-2025 | Rytary, Crexont, Lyvispah |
| Avanir Pharmaceuticals, INC. | $294.38 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $276.92 | 2021-2024 | Acthar |
| Mdd US Operations, LLC | $241.27 | 2019-2023 | Gocovri |
| Ge Healthcare | $234.55 | 2019-2025 | |
| Banner Life Sciences, LLC | $224.80 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $219.66 | 2022 | |
| Merz Pharmaceuticals, LLC | $203.41 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Arbor Pharmaceuticals, INC. | $186.23 | 2019-2022 | |
| Harmony Biosciences LLC | $176.17 | 2021-2023 | Wakix |
| Supernus Pharmaceuticals, INC. | $170.80 | 2019-2022 | |
| Sk Life Science, INC. | $166.40 | 2024-2025 | |
| Cycle Pharmaceuticals INC | $163.06 | 2024-2025 | Tascenso Odt, Bafiertam |
| Jazz Pharmaceuticals INC. | $154.47 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $113.13 | 2023 | Aptiom |
| Axsome Therapeutics, INC. | $108.68 | 2025 | Sunosi, Symbravo |
| Impel Pharmaceuticals LLC | $107.67 | 2025 | Trudhesa |
| Akcea Therapeutics, INC. | $88.72 | 2019-2021 | |
| Merz North America, INC. | $77.38 | 2019-2020 | |
| Neurelis, INC. | $76.93 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.64 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $72.58 | 2023-2025 | Horizant, Horizant |
| Grifols USA, LLC | $68.86 | 2025 | Gamunex-C |
| Averitas Pharma INC. | $57.43 | 2023-2024 | Qutenza |
| Zyla Life Sciences, INC. | $55.84 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.11 | 2021-2023 | Evusheld |
| Bausch Health US, LLC | $44.91 | 2019 | |
| Almatica Pharma LLC | $41.98 | 2021-2023 | Gralise |
| Livanova USA, INC. | $40.82 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Sandoz INC. | $39.12 | 2024 | |
| Grt US Holding, INC. | $38.79 | 2022 | |
| Tersera Therapeutics LLC | $37.23 | 2019-2021 | |
| Mylan Specialty L.P. | $36.23 | 2024 | Glatiramer Acetate |
| Bioventus LLC | $24.45 | 2023 | L300 Go System |
| Corium, LLC | $24.22 | 2023 | Adlarity |
| Boston Scientific Corporation | $21.81 | 2024 | |
| C2n Diagnostics, LLC | $21.37 | 2025 | Precivityad2 |
| Impel Pharmaceuticals INC. | $18.51 | 2022 | |
| Revance Therapeutics, INC. | $18.16 | 2025 | Daxxify |
| Janssen Biotech, INC. | $18.04 | 2025 | |
| Xeris Pharmaceuticals, INC. | $17.85 | 2022 | |
| Tanabe Pharma America, INC. | $16.77 | 2023 | |
| Scilex Pharmaceuticals INC. | $16.55 | 2023 | Ztlido |
| Assertio Therapeutics, INC. | $15.59 | 2019 | |
| Insightec,INC | $14.42 | 2023 | Exablate |
| Medtronic USA, INC. | $13.92 | 2020 | |
| Collegium Pharmaceutical, INC. | $13.65 | 2022 | |
| Dynasplint Systems INC. | $12.81 | 2023 | Dynasplint |
| Avion Pharmaceuticals | $12.64 | 2022 | |
| Kyowa Kirin, INC. | $12.58 | 2021 | |
| Currax Pharmaceuticals LLC | $12.33 | 2020 | |
| Portola Pharmaceuticals, LLC | $11.64 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.22 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,113.93 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cascione listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.